Extracellular aaRSs drive autoimmune and inflammatory responses in rheumatoid arthritis via the release of cytokines and PAD4
Conclusions
Our findings uncovered the significant role of aaRSs as a novel alarmin in RA pathogenesis, indicating that their blocking agents are potent antirheumatic drugs. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - August 11, 2023 Category: Rheumatology Authors: Kimura, A., Takagi, T., Thamamongood, T., Sakamoto, S., Ito, T., Seki, I., Okamoto, M., Aono, H., Serada, S., Naka, T., Imataka, H., Miyake, K., Ueda, T., Miyanokoshi, M., Wakasugi, K., Iwamoto, N., Ohmagari, N., Iguchi, T., Nitta, T., Takayanagi, H., Yam Tags: ARD, Rheumatoid arthritis Source Type: research
Cytokine-directed cellular cross-talk imprints synovial pathotypes in rheumatoid arthritis
Conclusion
Our study highlights the role of cytokine-activated FLS in orchestrating inflammation-associated synovial pathotypes providing novel insights into disease mechanisms of RA. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - August 11, 2023 Category: Rheumatology Authors: Kugler, M., Dellinger, M., Kartnig, F., Müller, L., Preglej, T., Heinz, L. X., Simader, E., Göschl, L., Puchner, S. E., Weiss, S., Shaw, L. E., Farlik, M., Weninger, W., Superti-Furga, G., Smolen, J. S., Steiner, G., Aletaha, D., Kiener, H Tags: ARD, Rheumatoid arthritis Source Type: research
Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme
Conclusions
An increased risk of MACE, malignancy (excluding NMSC) and VTE was observed in higher-risk populations with RA, yet risk was comparable between upadacitinib-treated and adalimumab-treated patients. Higher rates of NMSC and HZ were observed with upadacitinib versus comparators across all populations, and increased rates of serious infections were detected in upadacitinib-treated patients at higher CV risk.
Trial registration numbers
NCT02706873, NCT02675426, NCT02629159, NCT02706951, NCT02706847 and NCT03086343. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - August 11, 2023 Category: Rheumatology Authors: Fleischmann, R., Curtis, J. R., Charles-Schoeman, C., Mysler, E., Yamaoka, K., Richez, C., Palac, H., Dilley, D., Liu, J., Strengholt, S., Burmester, G. Tags: Open access, ARD, Rheumatoid arthritis Source Type: research
Approach to vaccination in systemic lupus erythematosus on biological treatment
In recent years, treat-to-target strategy and early intervention strategies with immunosuppressive agents have attempted to improve the prognosis and outcome in patients with autoimmune inflammatory rheumatic diseases. However, infectious complications due to side effects of medication remain a major concern in routine practice. In this regard, vaccine immunity and vaccination programmes are of the utmost importance in patients with systemic lupus erythematosus (SLE) in terms of morbidity and mortality. Encouragingly, research investigations have increased exponentially, both in monitoring the vaccines efficacy, and in det...
Source: Annals of the Rheumatic Diseases - August 11, 2023 Category: Rheumatology Authors: Yıldırım, R., Oliveira, T., Isenberg, D. A. Tags: Editor's choice, ARD Lay summaries, ARD Reviews Source Type: research
Correction: Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials
van der Heijde D, Deodhar A, Baraliakos X, et al. Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials. Ann Rheum Dis 2023;82:515-26. doi: 10.1136/ard-2022-223595
Although the results were presented correctly, the summary in the discussion needs to be corrected:
‘Most fungal infections with bimekizumab were mild to moderate, and none were systemic or led to treatment discontinuation.’
Correct sentence:
‘Most cases of fungal infections with bimekizumab were mild to moderate, with only 2 leading to discontinuation, and no systemic fungal...
Source: Annals of the Rheumatic Diseases - August 11, 2023 Category: Rheumatology Tags: Open access, ARD Correction Source Type: research
Correspondence on 'The use of tocilizumab and tofacitinib in patients with resolved hepatitis B infection: a case series
We read with great interest the article ‘The use of tocilizumab and tofacitinib in patients with resolved hepatitis B infection: a case series’ by Serling-Boyd et al.1 In this article, the authors conducted a retrospective study and examined the safety of tocilizumab (TCZ) and tofacitinib (TOF) in patients with resolved hepatitis B virus (HBV) infection defined as HB surface antigen (HBsAg)-negative, HB surface antibody (HBsAb)-positive and/or HB core antibody (HBcAb)-positive status. According to the authors, none of the patients developed HBV reactivation, leading to the conclusion that TCZ and TOF may be saf...
Source: Annals of the Rheumatic Diseases - August 11, 2023 Category: Rheumatology Authors: Watanabe, R., Hashimoto, M., Morinobu, A. Tags: ARD Correspondence Source Type: research
COVID-19 in Italian patients with rheumatic autoimmune systemic diseases
We followed with great interest the numerous reports published by the Annals1–9 as regards the impact of the COVID-19 pandemic on different rheumatic autoimmune systemic diseases (ASD), including the survey study by Costa et al9 that underlined the usefulness of telerheumatology in the management of patients with psoriatic arthritis in COVID-19 era. On the same topic, the world literature encompasses a large number of anecdotal observations, cohort studies and telephone surveys.1–15 Overall, the observed prevalence of symptomatic COVID-19, usually as mild-moderate disease, in patients with chronic arthritis was...
Source: Annals of the Rheumatic Diseases - August 11, 2023 Category: Rheumatology Authors: Ferri, C., Giuggioli, D., Raimondo, V., Fallahi, P., Antonelli, A., on behalf of the COVID-19 & ASD Italian Study Group, COVID-19 & ASD Italian Study Group, Ferri, Giuggioli, Spinella, Raimondo, Brittelli, Aiello, Caminiti, LAndolina, Tavoni, Bilia, Giann Tags: ARD, COVID-19 Correspondence Source Type: research
Correspondence on 'The 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4-Related Disease
IgG4-related disease (IgG4-RD) is a multisystem fibroinflammatory disorder diagnosed and managed across a broad spectrum of specialities. The American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria for IgG4-RD, recently published in this journal,1 provide robust and validated measures for discrimination from disease mimics with excellent test performance. The classification criteria incorporates three domains: entry, exclusion and inclusion criteria, with numerically weighted inclusion criteria reaching a score of 20 points or more to support a diagnosis of IgG4-RD. We soug...
Source: Annals of the Rheumatic Diseases - August 11, 2023 Category: Rheumatology Authors: Peters, R. J. R., Martin, H., Virdee, A., Fryer, E., Bungay, H., Rodriguez-Justo, M., Chouhan, M., Barnes, E., Webster, G., Culver, E. L. Tags: ARD Correspondence Source Type: research
Correspondence on '2018 update of the EULAR recommendations for the management of hand osteoarthritis
We were inspired by reading the article entitled ‘2018 update of the EULAR recommendations for the management of hand osteoarthritis’ by Kloppenburg et al.1 This up-to-date guideline will inform all health professionals and patients about optimal management by shared decision-making and may help advance research of hand osteoarthritis (OA). In overarching principles, this recommendation highlighted that the primary goal of managing hand OA is to control pain and stiffness and to optimise hand function and quality of life. This guideline also emphasised that management of hand OA should be individualised, taking...
Source: Annals of the Rheumatic Diseases - August 11, 2023 Category: Rheumatology Authors: Suh, Y. S., Kim, H.-O., Lee, C. H., Yoon, C. H., Cheon, Y.-H., Kim, M., Lee, H., Lee, S.-I. Tags: ARD Correspondence Source Type: research
Response to: Correspondence on 'Mechanical overloading promotes chondrocyte senescence and osteoarthritis development through downregulating FBXW7 by Loeser et al
In January 2022, we reported an important role for FBXW7 in the association between mechanical overloading, chondrocyte senescence and cartilage ageing in the pathology of osteoarthritis (OA).1 Our data support the idea that JNK signalling pathway is activated in OA, and DTP3 can inhibit JNK in chondrocytes.1 Two of our observations have been challenged by Dr. Richard F. Loeser and Dr. Philip R. Coryell. We thank Dr. Loeser and Dr. Coryell for their thoughtful correspondence. While their comments have promoted us to take another critical look at our data and interpretations, we think that their remarks and the associated r...
Source: Annals of the Rheumatic Diseases - August 11, 2023 Category: Rheumatology Authors: Zhang, H., Cai, D., Bai, X. Tags: ARD Correspondence response Source Type: research
Correspondence on 'Mechanical overloading promotes chondrocyte senescence and osteoarthritis development through downregulating FBXW7
The recent publication in the Annals of Rheumatic Diseases by Zhang et al1 ‘Mechanical overloading promotes chondrocyte senescence and osteoarthritis development through downregulating FBXW7’ includes conclusions that ‘inhibition of JNK activity ameliorated chondrocyte senescence and cartilage degeneration’ and ‘this study suggests that targeting FBXW7–MKK7–JNK signalling may be a novel therapeutic approach for osteoarthritis (OA) treatment’. We were surprised to see these conclusions since we found very different results in a recent study2 examining the role of JNK signallin...
Source: Annals of the Rheumatic Diseases - August 11, 2023 Category: Rheumatology Authors: Loeser, R. F., Coryell, P. R. Tags: ARD Correspondence Source Type: research
Response to: Correspondence on "ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update" by Braun et al
We read with interest the letter by Braun1 pertaining to the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis (axSpA).2 Braun questions whether having non-steroidal anti-inflammatory drugs (NSAIDs) as the first mandatory pharmacological treatment is still appropriate. First, doubt is raised whether an insufficient response to NSAIDs, which is required in daily clinical practice and in clinical studies before the start of biological disease-modifying antirheumatic drugs (bDMARDs), is ever formally checked. Whether this is the case or not, we remain firmly of the opinion that this c...
Source: Annals of the Rheumatic Diseases - August 11, 2023 Category: Rheumatology Authors: Ramiro, S., Nikiphorou, E., Sepriano, A., Ortolan, A., Webers, C., Baraliakos, X., Landewe, R. B., van der Heijde, D. Tags: ARD Correspondence response Source Type: research
Correspondence on "ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update"
With great interest I read the recently published Assessment of Spondyloarthritis International Society (ASAS/European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of axial spondyloarthritis (axSpA,1), which included some but not many changes in comparison to the last recommendations.1 Let me first say that I largely agree with them. However, I would like to initiate a discussion related to the recommendation related to treatment with non-steroidal anti-inflammatory drugs (NSAIDs) in order to possibly change this recommendation in the next update. NSAIDs were clearly shown to work in...
Source: Annals of the Rheumatic Diseases - August 11, 2023 Category: Rheumatology Authors: Braun, J. Tags: ARD Correspondence Source Type: research
Response to: Correspondence on "HLA-DR 'naturally presented peptides: you will find what you have pulsed with" by Roudier
We appreciate Dr Roudier’s interest and comment on our recent article.1 2 The aim of our study was to analyse the human leukocyte antigen (HLA)-DR-associated peptidome of synovial tissue (ST) and of dendritic cells (DCs) pulsed with synovial fluid (SF) or ST, to identify epitopes that trigger T cell responses in patients with rheumatoid arthritis (RA). Dr Roudier is indeed correct when he asserts that our study is biased toward the synovium. However, we consider that ours is not a ‘conception bias’ but a deliberate effort to focus our attention on a particular tissue as a source of autoantigens, incidenta...
Source: Annals of the Rheumatic Diseases - August 11, 2023 Category: Rheumatology Authors: Catalan, D., Jaraquemada, D., Aguillon, J. C. Tags: ARD Correspondence response Source Type: research
Correspondence on "Isolation of HLA-DR-naturally presented peptides identifies T-cell epitopes for rheumatoid arthritis"
The article titled ‘Isolation of HLA-DR naturally presented peptides identifies T cell epitopes for rheumatoid arthritis’ reports the elution and characterisation by mass spectrometry of ‘naturally processed’ peptides from the synovial fluid and synovium of patients with rheumatoid arthritis.1 It uses state of the art technology to produce monocyte-derived dendritic cells and analyse the peptides associated with their Human Leucocyte Antigen DR molecules by mass spectrometry. However, the whole project is based on the a priori hypothesis that RA develops in the synovium and that only synovium-derive...
Source: Annals of the Rheumatic Diseases - August 11, 2023 Category: Rheumatology Authors: Roudier, J. Tags: ARD Correspondence Source Type: research
